Analysts’ Recent Ratings Updates for Nurix Therapeutics (NRIX)

A number of research firms have changed their ratings and price targets for Nurix Therapeutics (NASDAQ: NRIX):

• 10/27/2025 – Nurix Therapeutics had its price target lowered by analysts at HC Wainwright from $33.00 to $28.00. They now have a “buy” rating on the stock.
• 10/23/2025 – Nurix Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $22.00 to $21.00. They now have an “overweight” rating on the stock.
• 10/23/2025 – Nurix Therapeutics had its price target lowered by analysts at BTIG Research from $35.00 to $27.00. They now have a “buy” rating on the stock.
• 10/22/2025 – Nurix Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $29.00 price target on the stock.
• 10/21/2025 – Nurix Therapeutics is now covered by analysts at Mizuho. They set an “outperform” rating and a $24.00 price target on the stock.
• 10/20/2025 – Nurix Therapeutics was upgraded by analysts at Mizuho to a “strong-buy” rating.
• 10/20/2025 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $27.00 price target on the stock.
• 10/20/2025 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
• 10/14/2025 – Nurix Therapeutics had its price target lowered by analysts at HC Wainwright from $34.00 to $33.00. They now have a “buy” rating on the stock.
• 10/14/2025 – Nurix Therapeutics had its price target lowered by analysts at Morgan Stanley from $16.00 to $15.00. They now have an “equal weight” rating on the stock.
• 10/13/2025 – Nurix Therapeutics was given a new $22.00 price target on by analysts at Wells Fargo & Company.
• 10/11/2025 – Nurix Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating.
• 10/10/2025 – Nurix Therapeutics was given a new $33.00 price target on by analysts at Stifel Nicolaus.
• 10/10/2025 – Nurix Therapeutics had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $30.00 to $28.00. They now have an “outperform” rating on the stock.
• 10/10/2025 – Nurix Therapeutics had its price target lowered by analysts at Piper Sandler from $35.00 to $32.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,130 shares of the business’s stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $12.80, for a total value of $40,064.00. Following the sale, the chief financial officer owned 43,876 shares of the company’s stock, valued at $561,612.80. The trade was a 6.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gwenn Hansen sold 4,087 shares of Nurix Therapeutics stock in a transaction dated Thursday, October 30th. The shares were sold at an average price of $12.80, for a total value of $52,313.60. Following the completion of the transaction, the insider directly owned 76,751 shares of the company’s stock, valued at approximately $982,412.80. This represents a 5.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 7.40% of the stock is owned by insiders.

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.